Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials-Reference-Cited by-同舟云学术

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

Published:2021-10 Issue: Volume:Volume 15 Page:4035-4048
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Wirta David L,Korenfeld Michael S^ORCID,Foster Shane^ORCID,Smyth-Medina Robert,Bacharach Jason,Kannarr Shane R,Jaros Mark J,Slonim Charles B

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference51 articles.

1. Comparison of Automated and Manual Perimetry in Patients With Blepharoptosis

2. The Effect of Blepharoptosis on the Field of Vision

3. Severity of Visual Field Loss and Health-related Quality of Life

4. Evaluating the Visual Field Effects of Blepharoptosis Using Automated Static Perimetry

5. Ptosis: Causes, Presentation, and Management

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Oxymetazoline 0.1% Ophthalmic Solution for Acquired Blepharoptosis: A Systematic Review;The Laryngoscope;2024-08-22

2. Use of oxymetazoline hydrochloride ophthalmic solution, 0.1% for improved lid symmetry in Graves’ disease;Orbit;2024-08-19

3. A review of nonsurgical facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1% in periorbital revitalization;Journal of Cosmetic Dermatology;2024-02-13

4. The Prevalence and Severity of Acquired Blepharoptosis in US Eye Care Clinic Patients and Their Receptivity to Treatment;Clinical Ophthalmology;2024-01

5. Botulinum Toxin Treatment in Aesthetic Medicine;Botulinum Toxin Treatment;2024